| Drug / Therapy | batoclimab |
| Indication | chronic inflammatory demyelinating polyneuropathy |
| Decision Type | PDUFA |
| Conditions | chronic inflammatory demyelinating polyneuropathy |
| Interventions | batoclimab |
Immunovant Inc (IMVT) operates in the Autoimmune sector. The current BTS Score is 43 (Grade: D).
Biotech companies frequently raise capital through secondary offerings, ATM programs, and convertible notes. Before or after major FDA decisions, dilution events are common. Understanding a company's dilution history is critical for managing risk around catalyst dates.
The PDUFA date for batoclimab by Immunovant Inc (IMVT) is scheduled for March 15, 2027. This is the target date for the FDA to make a decision on this application.
batoclimab is being developed by Immunovant Inc for the treatment of chronic inflammatory demyelinating polyneuropathy. It is under FDA review.
If batoclimab receives FDA approval, Immunovant Inc (IMVT) would be able to market the drug in the United States for chronic inflammatory demyelinating polyneuropathy. This typically leads to significant stock price movement for biotech companies. Investors should monitor the PDUFA date closely.
Biotech companies often raise capital through share offerings, which can dilute existing shareholders. You can check the current dilution risk for IMVT on DilutionWatch at dilutionwatch.com/stock/IMVT.html.
You can view the full BiotechSign company profile for Immunovant Inc (IMVT) at biotechsign.com/app/company/IMVT, which includes the BTS Score, signal history, clinical trial data, and insider trading activity.
This page is for informational purposes only and does not constitute investment advice. FDA decision dates are subject to change. Clinical trial outcomes are inherently uncertain. Biotech stocks are highly volatile — past performance does not guarantee future results. Always consult a qualified financial advisor before making investment decisions. BiotechSign is not a registered investment advisor.